Molecular docking, QSAR and AMDET analysis of 6-methyl-1,3,8-trichlorodibenzofuran and its analogs against estrogen receptor alpha

Medicinal Chemistry Research

Volumn 23, Issue 11, 2014, Pages 4724-4748

  Naidu, C Kumaraswamy ^a   Suneetha, Y ^a  

^a SRI VENKATESWARA UNIVERSITY   (India)

Author keywords

6 methyl 1,3,8 trichlorodibenzofuran; Docking; Estrogen receptor alpha; Virtual screening

Indexed keywords

EID: 84928886588     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-014-1039-4     Document Type: Article

References (18)

1. Astroff B, Zacharewski T, Safe S, Arlotto MP, Parkinson A, Thomas P, Levin W (1988) 6-Methyl-1,3,8-trichlorodibenzofuran as a 2,3,7,8-tetrachlorodibenzo-p-dioxin antagonist: inhibition of the induction of rat cytochrome P-450 isozymes and related monooxygenase activities. Mol Pharmacol 33(2):231-236
2. Bolton EE, Chen J, Kim S, Han L, He S, Shi W, Simonyan V, Sun Y, Thiessen PA, Wang J, Yu B, Zhang J, Bryant SH (2011) PubChem3D: a new resource for scientists. J Cheminform 3(1):32. doi:10.1186/1758-2946-3-32
3. Dallakyan S (2008-2010) PyRx-Python Prescription v.0.8.. The Scripps Research Institute, La Jolla
4. Dykstra KD, Guo L, Birzin ET, Chan W, Yang YT, Hayes EC, DaSilva CA, Pai LY, Mosley RT, Kraker B, Fitzgerald PM, DiNinno F, Rohrer SP, Schaeffer JM, Hammond ML (2007) Estrogen receptor ligands. Part 16: 2-Aryl indoles as highly subtype selective ligands for ERalpha. Bioorg Med Chem Lett 17(8):2322-2328. doi:10.1016/j.bmcl.2007.01.054
5. Girault I, Bieche I, Lidereau R (2006) Role of estrogen receptor alpha transcriptional coregulators in tamoxifen resistance in breast cancer. Maturitas 54(4):342-351. doi:10.1016/j.maturitas.2006.06.003
6. Leeson P (2012) Drug discovery: chemical beauty contest. Nature 481(7382):455-456. doi:10.1038/481455a
7. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46(1-3):3-26
8. Liu W, Konduri SD, Bansal S, Nayak BK, Rajasekaran SA, Karuppayil SM, Rajasekaran AK, Das GM (2006) Estrogen receptor-alpha binds p53 tumor suppressor protein directly and represses its function. J Biol Chem 281(15):9837-9840. doi:10.1074/jbc.C600001200
9. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ (2009) AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 30(16):2785-2791. doi:10.1002/jcc.21256
10. Onland-Moret NC, van Gils CH, Roest M, Grobbee DE, Peeters PH (2005) The estrogen receptor alpha gene and breast cancer risk (The Netherlands). Cancer Causes Control 16(10):1195-1202. doi:10.1007/s10552-005-0307-5
11. Pearce ST, Liu H, Radhakrishnan I, Abdelrahim M, Safe S, Jordan VC (2004) Interaction of the aryl hydrocarbon receptor ligand 6-methyl-1,3,8-trichlorodibenzofuran with estrogen receptor alpha. Cancer Res 64(8):2889-2897
12. Platet N, Cathiard AM, Gleizes M, Garcia M (2004) Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion. Crit Rev Oncol Hematol 51(1):55-67. doi:10.1016/j.critrevonc.2004.02.001
13. Sanchez AM, Flamini MI, Baldacci C, Goglia L, Genazzani AR, Simoncini T (2010) Estrogen receptor-alpha promotes breast cancer cell motility and invasion via focal adhesion kinase and N-WASP. Mol Endocrinol 24(11):2114-2125. doi:10.1210/me.2010-0252
14. Shanle EK, Xu W (2010) Selectively targeting estrogen receptors for cancer treatment. Adv Drug Deliv Rev 62(13):1265-1276. doi:10.1016/j.addr.2010.08.001
15. Singletary SE (2003) Rating the risk factors for breast cancer. Ann Surg 237(4):474-482. doi:10.1097/01.SLA.0000059969.64262.87
16. Tusar M, Minovski N, Fjodorova N, Novic M (2012) In silico assessment of adverse effects of a large set of 6-fluoroquinolones obtained from a study of tuberculosis chemotherapy. Curr Drug Saf 7(4):313-320
17. VegaNIC-1.0.6-binaries (2013)
18. Vyas VK, Ghate M, Goel A (2013) Pharmacophore modeling, virtual screening, docking and in silico ADMET analysis of protein kinase B (PKB beta) inhibitors. J Mol Graph Model 42:17-25. doi:10.1016/j.jmgm.2013.01.010